ALK inhibitors in the treatment of patients with NSCLC

01/2017

MUDr. Libor Havel

Pneumologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

 

SUMMARY

Patients with EML4-ALK translocation represent small, but clinically interesting subgroup of patients with non-small cell lung cancer. Since this genetic alteration revealing we are witness of rapid progress in therapy of these patients. ALK (anaplastic lymphoma kinase) inhibitors became a standard therapy in first line treatment, second generation ALK inhibitors are available in clinical practice and higher lines are tested. This article would be a summarisation of recent attitude to ALK inhibitors in NSCLC.

 

KEY WORDS

non-small cell lung cancer, crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, entrectinib, resistance

 

 

Celý článek je dostupný pouze pro předplatitele

Staňte se pravidelným odběratelem našeho časopisu Onkologická revue...

 

VÍCE O PŘEDPLATNÉM